AstraZeneca: TAGRISSO Plus Chemotherapy Extended Median Progression-Free Survival by Nearly 9 Months in EGFR-Mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
September 13, 2023
September 13, 2023
WILMINGTON, Delaware, Sept. 13 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Sept. 11, 2023:
Positive results from the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) ep . . .
Positive results from the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) ep . . .